UK-based CDMO Aesica has announced that it will expand its services related to inhalation product development and manufacturing at its Nottingham site and that it plans to open a new inhalation technical center in late 2014. The company said that it has recently added spray drying and powder filling capabilities, as well as a number of new hires in the inhalation area.
According to Aesica, “The Nottingham site currently has over 5 years’ experience developing new generic inhalation products alongside many New Chemical Entities (NCE) for trial. Aesica is increasingly looking to work with clients over the longer term and is concentrating on taking new drug targets right through to commercial stage, with the ability to switch easily between initial nebulized products . . . and dry powder inhalers for use in later clinical trials.”
Site Director Ian Lafferty explained the company’s increased focus on OINDPs: “Inhalation is a rapidly growing market with many US companies looking to bring NCE production to Europe, whilst we also see a dramatic growth for products going into China and SE Asia, particularly amongst generic formulations. We have largely operated under the radar in terms of inhalation products despite the wealth of new technologies coming to market here and our intention is to take a lead in bringing products to market faster and developing the next generation of technologies through our Lead Technical Centre.”
Read the Aesica press release.
